Yingxian Qian

Ms. Yingxian Qian

Department of Pathology, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Beijing, P.R. China, Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YQYingxian Qian
Yingxian Qian
SMShengwei Mo
Shengwei Mo
XCXiaoyan Chang
Xiaoyan Chang
We reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015–2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN’s biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm. English-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024. Significant advancements have been achieved in IOPN research. Molecular investigations discover several immunohistochemical markers which may facilitate the diagnosis of IOPN, including CD117, HepPar-1. Significantly ATP1B1::PRKACA, DNAJB1::PRKACA and ATP1B1::PRKACB gene fusions are identified as molecular hallmarks of IOPN. These genetic alterations are believed to activate the cAMP-PKA signaling pathway, subsequently influencing mitochondrial substrates and contributing to the development of oncocytic features. The molecular signature not only enhances diagnostic specificity but also presents potential therapeutic targets. Furthermore, IOPN exhibits a unique tumor immune microenvironment characterized by elevated PD-L1 expression and substantial inflammatory cell infiltration. The invasive component showed decrease in CD4 + T cells and increase in CD8 + T cells and macrophages suggested the existence of an active immune surveillance, which partially explained why IOPN could have a better prognosis. IOPN exhibits distinct genetic alterations and a unique immune microenvironment. These features not only elucidate the mechanism underlying the relatively favorable prognosis of IOPN and IOPN-derived pancreatic cancers but also offer novel insights into immune regulation strategies for pancreatic cancer.

9 April 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
ZHZhaoxia Huang
Zhaoxia Huang
QLQijun Li
Qijun Li
YWYuan Wang
Yuan Wang
YQYingxian Qian
Yingxian Qian
RCRuixue Cui
Ruixue Cui

13 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZQZijun Qiu
Zijun Qiu
ASAodeng Surita
Aodeng Surita
XWXiaowei Wang
Xiaowei Wang
YQYingxian Qian
Yingxian Qian
ZZZhenzhen Zhu
Zhenzhen Zhu
WLWei Lv
Wei Lv
Objectives: We aimed to characterize the clinicopathologic features, treatment, and outcomes of three types of Switch/Sucrose Nonfermentable (SWI/SNF)-deficient sinonasal carcinomas (SDSCs), thereby expanding the spectrum of these rare entities and facilitating early diagnosis. Methods: We designed a retrospective single-center case series to analyze the clinicopathological features of 17 patients with SMARCB1-deficient sinonasal carcinoma (n = 10), SMARCA4-deficient carcinoma (n = 6) and SMARCA4-deficient sinonasal teratocarcinosarcoma (TCS) (n = 1) treated between 2018 and 2025, and reviewed the relevant literature. Results: The cohort included 14 males and 3 females, aged 26 to 69 years (mean, 47 years). SMARCB1-deficient sinonasal carcinomas predominantly involved the ethmoid sinus (6 of 8 patients), presenting epistaxis (7 of 10 patients), nasal obstruction (5 of 10 patients), and ocular symptoms (4 of 10 patients). SMARCA4-deficient sinonasal carcinomas mainly arose in the nasal cavity (3 of 4 patients), characterized by nasal obstruction (4 of 6 patients), and epistaxis or purulent rhinorrhea (4 of 6 patients); ocular symptoms were less common (2 of 6 patients). The TCS patient had left nasal cavity and ethmoid involvement with nasal obstruction and purulent rhinorrhea. Most patients presented with advanced-stage disease (T4a, n = 9), with skull base (n = 6), and orbital (n = 3) involvement. Histologically, immunohistochemical analysis confirmed complete SMARCB1 or SMARCA4 loss (complete in carcinomas and partial in TCS), diffuse CK positivity, and high Ki-67 indices. Treatment modalities included: chemotherapy and immunotherapy without surgery (n = 2), radical surgery with adjuvant chemoradiotherapy and immunotherapy (n = 2), radical surgery with chemoradiotherapy (n = 9), postoperative radiotherapy alone (n = 3), and non-radical surgery with chemoradiotherapy (n = 1). At a median follow-up of 19 months (range, 8–57 months), 2 patients were lost to follow-up, 3 died, 2 had persistent disease, and 10 remained disease-free. Conclusions: SDSC is an aggressive tumor with male predominance and advanced-stage presentation. Early recognition and appropriate immunohistochemical evaluation are essential for timely diagnosis and management. Prospective studies of novel targeted and immunotherapeutic strategies are warranted.